Moroccan businesswoman Lamia Tazi’s stake in Sothema nears $90 million

Key Points

• Tazi’s 8.19% stake nears $90 million, seeing a further increase of $12.78 million in 21 days, amid a sustained stock rally on the Casablanca Bourse.
• Sothema’s stock price jumped from $130 on April 30 to $151.7, increasing the company’s market capitalization to nearly $1 billion and rewarding shareholders with robust returns.
• Sothema has achieved a year-to-date gain of 51.35%, reflecting its growing international presence and investor confidence in Tazi’s leadership.

Lamia Tazi, a top figure in Morocco’s pharmaceutical industry, has seen the market value of her stake in the company approach the $90 million mark. This boost comes on the heels of a strong rally in Sothema’s share price on the Casablanca Bourse, underscoring renewed investor confidence.

Investor confidence lifts Sothema stake to new highs

Tazi, who serves as CEO of Sothema, holds an 8.19 percent stake in the pharmaceutical company—equivalent to 589,658 shares. Over the past 18 days, Sothema’s stock has rallied on the Casablanca Bourse, boosting the market value of her stake by MAD117.93 million ($12.78 million).

This recent surge builds on an earlier gain of $14.93 million recorded between April 7 and April 25, when the value of her holdings climbed from MAD586.71 million ($63.2 million) to MAD725.28 million ($78.12 million). The continued rise reflects growing investor confidence in Sothema’s performance and the broader resilience of Morocco’s pharmaceutical sector.

Sothema exceeds $1 billion valuation after 16.67% stock rally

Sothema, Morocco’s healthcare company, produces about 60 million pharmaceutical units each year and partners with 35 multinational laboratories. Its products are distributed across Europe, the Maghreb, Sub-Saharan Africa, and the Persian Gulf, reflecting its key role in the region’s healthcare supply chain.

Over the past 21 days, shares of Sothema have surged 16.67 percent on the Casablanca Bourse, pushing the company’s market capitalization close to the $1 billion mark. The stock rose from MAD1,200 ($130.06) on April 30 to MAD1,400 ($151.74) at the time of reporting, delivering strong returns for shareholders. 

Investor optimism fuels $12.78 million gain

This rally significantly boosted the value of CEO Lamia Tazi’s 8.19 percent stake in the pharmaceutical giant. Her holdings increased by MAD117.93 million ($12.78 million), climbing from MAD707.59 million ($76.69 million) to MAD825.52 million ($89.47 million), cementing her position among the Casablanca Bourse’s most prominent investors.

This highlights growing investor confidence in Tazi’s leadership as she steers Sothema’s expansion and operational momentum. Her rising fortune mirrors the company’s expanding footprint in international markets, reinforcing its status as a leading force in North Africa’s pharmaceutical sector.

Your money and your life

This rally reflects rising investor confidence and the company’s expanding footprint in major international markets, reinforcing its pivotal role in North Africa’s healthcare landscape. For investors, a $100,000 investment in Sothema at the start of 2025 would now be worth $151,350—delivering a substantial gain of $51,350 and showcasing the company’s strong return potential.